TABLE 9.
Future potentials of nanoparticle-antibiotics synergy.
| Nanoparticle | Antibiotics | Properties | Antibacterial mechanisms | References |
|---|---|---|---|---|
| Fullerene (C60) | Vancomycin | 1. Unique carbon cage structures, size, hydrophobicity, electronic configurations, and three-dimensionality | 1. Disruption of membrane integrity in bacteria | Bakry et al. (2007); Tang et al. (2007); Prylutskyy et al. (2014) |
| 2. Production of high quantum yield singlet oxygen | 2. Fullerene interacts with the hydrophobic cavity of enzymes and thus inhibits enzyme activity | |||
| 3. Can cleave DNA due to the electron transfer from excited state fullerene to DNA base | 3. Induce oxidative stress | |||
| 4. For hybrid nanostructures, fullerene provides high encapsulation efficiency with lipidic NPs | 4. Perturb energy metabolism | |||
| 5. Interact with cytochrome P450S, cysteine, and serine proteases | ||||
| 6. Cationic fullerenes react with negatively charged bacterial surfaces and the potential to disintegrate cell membranes by redox damage or mechanical breakage of the lipid bilayer | ||||
| Carbon quantum dots (CDQs) | Ciprofloxacin hydrochloride | 1. High ciprofloxacin loading capacity | 1. Controlled release of Ciprofloxacin at a slower rate from the surface of CDQs | Thakur et al. (2014) |
| 2. Avoid non-specific deposition, only reach the site of infection | 2. Deliver high concentration of antibiotic | |||
| 3. Can be used as a molecular-tag to locate the infection site in a host | 3. Various functional groups of CDQs inhibit cellular proliferation | |||
| 4. ROS generation from the charge-separated CDQs species | ||||
| Polymer | Penicillin, tetracycline, sulfonamide, fluoroquinolones | 1. Multifunctionality, good biocompatibility, and stable drug delivery both at in-vitro and in-vivo conditions | 1. As opposed to free antibiotics, polymeric NPs functionalized with antibiotics can overcome tissue barriers and improved penetration through cell wall and membranes | Xiong et al. (2014) |
| 2. Improved biodistribution and pharmacokinetics of antibiotics | 2. The synergy of polymeric NPs and antibiotics provide slow, sustained release of drug molecules at inaccessible specific site overcoming thick tissue layer | |||
| 3. Provides environmental deactivation | ||||
| 4. Due to being bioactive in nature, dose and frequency can be reduced | ||||
| Multiwall carbon nanotubes (MWCNTs) | Vancomycin | 1. MWCNT’s carboxyl group and Van’s amide group form a robust antibacterial conjugate | 1. Can effectively breakdown various human gut microbe’s membranes | Chen et al. (2013); Liu et al. (2017) |
| 2. This powerful agent can kill both Gram-positive and Gram-negative bacteria | 2. Rupture the DNA and RNA components, followed by the destruction of cell membranes | |||
| 3. Inhibit the biosynthesis of cell wall peptidoglycan and may reduce RNA synthesis | ||||
| Nanoemulsions | Erythromycin | 1. Overcome poor drug solubility | 1. Increased drug entrapment and loading efficiency enable high concentrated localized drug delivery | Sutradhar and Amin. (2013); Tran et al. (2017) |
| 2. long term activity | 2. Better drug absorption, penetration, and accurate dosing at target specific site ensure appropriate drug concentration, thereby reduces the chances of antibiotic resistance development | |||
| 3. Target specific | ||||
| 4. High retention time | ||||
| 5. Require low dose | ||||
| 6. Erythromycin stability improves under acidic condition | ||||
| 7. Enhancement of bioavailability | ||||
| 8. Better absorption inside cellular systems |